特布他林联合布地奈德对支气管哮喘急性发作患者肺功能及血清炎性因子水平的影响

Effect of Terbutaline Combined with Budesonide on Lung Function and Serum Inflammatory Factor Levels in Patients with Acute Exacerbations of Bronchial Asthma

目的探究特布他林联合布地奈德治疗支气管哮喘急性发作患者的临床疗效。方法选取郑州市金水区总医院2019年2月至2021年2月收治的72例支气管哮喘急性发作患者,随机分为对照组、研究组,各36例。两组均给予常规治疗,对照组予以布地奈德雾化吸入治疗,研究组予以特布他林+布地奈德序贯雾化吸入治疗。并比较两组临床疗效,临床症状改善情况,临床症状评分,肺功能指标[用力肺活量(FVC)、峰值呼气流速(PEF)、第1秒用力呼气容积(FEV1)/FVC],炎性因子[超敏C-反应蛋白(hs-CRP)、嗜酸粒细胞趋化因子-2(Eotaxin-2)、白介素-33(IL-33)、嗜酸粒细胞阳离子蛋白(ECP)]及不良反应发生率。结果研究组总有效率91.67%较对照组72.22%高(P<0.05);研究组咳嗽消失、喘息消失、哮鸣音消失及住院时间均短于对照组;治疗后研究组日间评分、夜间评分均低于对照组(P<0.05);治疗后研究组PEF、FVC、FEV1/FVC均高于对照组(P<0.05);治疗后研究组hs-CRP、Eotaxin-2、IL-33、ECP均低于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论特布他林联合布地奈德可改善支气管哮喘急性发作患者肺功能,并降低炎性因子表达,有利于临床症状缓解。

Objective To investigate the clinical efficacy of terbutaline in combination on with budesonide in the treatment of patients with acute exacerbations of bronchial asthma.Methods 72 patients admitted to Jinshui District General Hospital from February 2019 to February 2021 with acute exacerbation of bronchial asthma were selected and randomly divided into control and study groups of 36 cases each.Both groups were given conventional treatment,the control group was treated with budesonide nebulizer inhalation,and the study group was treated with terbutaline+budesonide sequential nebulizer inhalation.The clinical efficacy,improvement of clinical symptoms,clinical symptom scores,pulmonary function indexes[force spirometry(FVC),peak expiratory flow rate(PEF),force expiratory volume in the first second(FEV1)/FVC],inflammatory factors[hypersensitive C-reactive protein(hs-CRP),eosinophil chemotactic factor-2(Eotaxin-2),interleukin-33(IL-33),eosinophil cationic protein(ECP)]and the incidence of adverse reactions,between the two groups were compared.Results The total effective rate of the study group was 91.67%,which was higher than that of the control group 72.22%(P<0.05);the disappearance of cough,wheeze,croup and hospital stay were shorter in the study group than in the control group;the daytime and nighttime scores were lower in the study group than in the control group after treatment(P<0.05);the PEF,FVC and FEV1/FVC were higher in the study group than in the control group after treatment(P<0.05));hs-CRP,Eotaxin-2,IL-33,and ECP were lower in the study group than in the control group after treatment(P<0.05);there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Terbutaline combined with budesonide improves lung function and reduces inflammatory factor expression in patients with acute exacerbation of bronchial asthma,which facilitates clinical symptom relief.